Phase II-B VMAT-2 - Top line data mid-2013
Elagolix for Uterine Fibroids phase II-A ends March 0f 2013. Phase II-B starts in 2013.
Elagolix for Endometriosis in first Phase III study with top line data in 2014
Endometriosis 2nd Phase III starts in early 2013.
Abbvie's drug Lupron for endometriosis has a patent expiration in 2015.
Neuro's Urocortin 2 for congestive heart failure had a successful Phase II trial and is for sale or partnering with another pharma company. Neuro will not develop a heart drug on their own.
Lots of cash in the bank. No need to ever raise more stock.
Keep in mind that the uterine fibroid trial concluded in December. Could be that the data has been viewed...if positive it's going to run a heck of a lot more. You're getting into serious blockbuster territory at that point.